Biovica International AB Company Description

Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the United States of America.

It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation.

It serves cancer institutes, pharmaceutical companies, and collaborative groups. Biovica International AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.

Biovica International AB (publ)

Country	Sweden
Founded	2008
Industry	Biotechnology
Sector	Healthcare
Employees	32
CEO	Anders Rylander

Contact Details

Address: Dag HammarskjOelds vAeg 54B Uppsala, Uppsala County 752 37 Sweden
Phone	46 1 84 44 48 30
Website	biovica.com

Stock Details

Ticker Symbol	BIOVIC.B
Exchange	Nasdaq Stockholm
Fiscal Year	May - April
Reporting Currency	SEK
ISIN Number	SE0008613731
SIC Code	2835

Key Executives

Name	Position
Anders Rylander	President, Chief Executive Officer and Director
Anders Moren	Chief Financial Officer
Hanna Ritzén	Chief Operating Officer